Advertisement
UK markets close in 7 hours 35 minutes
  • FTSE 100

    8,062.54
    +38.67 (+0.48%)
     
  • FTSE 250

    19,657.88
    +58.49 (+0.30%)
     
  • AIM

    751.30
    +2.12 (+0.28%)
     
  • GBP/EUR

    1.1578
    -0.0011 (-0.10%)
     
  • GBP/USD

    1.2361
    +0.0011 (+0.09%)
     
  • Bitcoin GBP

    53,574.48
    +111.29 (+0.21%)
     
  • CMC Crypto 200

    1,392.62
    -22.14 (-1.56%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    82.40
    +0.50 (+0.61%)
     
  • GOLD FUTURES

    2,323.20
    -23.20 (-0.99%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,829.89
    +318.20 (+1.93%)
     
  • DAX

    17,977.16
    +116.36 (+0.65%)
     
  • CAC 40

    8,057.06
    +16.70 (+0.21%)
     

Orion raises outlook after Merck deal on developing prostate cancer drug

(Reuters) - Finnish drug maker Orion on Wednesday raised its full year outlook after it signed a collaboration agreement with Merck aimed at developing a prostate cancer drug candidate.

Given the upfront payment of $290 million Orion is to receive from Merck, the Finnish company now expects sales and operating profit in 2022 to be "clearly higher" than in 2021.

(Reporting by Boleslaw Lasocki; editing by Jason Neely)